Yahoo
NasdaqGS - Nasdaq Real Time Price USD

SpyGlass Pharma, Inc. (SGP)

26.86 +0.76 (+2.91%)
At close: September 1 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for SGP
  • Previous Close 26.10
  • Open 25.25
  • Bid 19.28 x 100
  • Ask 33.75 x 100
  • Day's Range 25.25 - 27.00
  • 52 Week Range 17.06 - 32.44
  • Volume 87,105
  • Avg. Volume 115,917
  • Market Cap (intraday) 898.413M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -1.68
  • Earnings Date (est.) Nov 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 44.00

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

www.spyglasspharma.com

76

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SGP
11.92%
S&P 500 (^GSPC)
11.48%

1-Year Return

SGP
11.92%
S&P 500 (^GSPC)
18.13%

3-Year Return

SGP
11.92%
S&P 500 (^GSPC)
69.00%

5-Year Return

SGP
11.92%
S&P 500 (^GSPC)
68.69%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -19.86M
Profit Margin 0.00%

Q4

FY25

Q1

FY26

Q2

FY26

-15M
-10M
-5M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

37.00
44.00 Average
26.86 Current
62.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst Raymond James
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 39

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    898.75M

  • Enterprise Value

    666.19M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.87

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -56.05M

  • Diluted EPS (ttm)

    -1.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    234.19M

  • Total Debt/Equity (mrq)

    0.70%

  • Levered Free Cash Flow (ttm)

    --

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

26.86 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: